Home/ Stocks/ ZURA

Zura Bio Limited Class A Ordinary Shares

ZURA XNAS

$4.79 +0.25 (+5.51%) ▲ 15-min delayed

Open

$4.42

High

$4.84

Low

$4.35

Volume

1.05M

Market Cap

$454.48M

About Zura Bio Limited Class A Ordinary Shares

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 40 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$0	$-68,650,000	$-1.06
FY 2025	$0	$-68,650,000	$-1.06
Q3 2025	$0	$-18,040,000	$-0.21
Q2 2025	$0	$-15,993,000	$-0.17

Related Market News

No specific coverage for ZURA yet. Check out our latest market news or earnings calendar.

Get ZURA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Zura Bio Limited Class A Ordinary Shares.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.